Interview, Fireside Chat
The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation
- AI is predicted to be universally adopted by the biotech industry within five years, with potential to reduce drug development costs from $2.5 billion to $500 million and accelerate timelines fourfold.
- Three companies are expected to commence first-in-human trials within the next 12 to 18 months, all avoiding the United States due to significant speed and cost advantages in China, including review timelines that are 5–6 weeks shorter.
- Increased competition from Chinese biotechs will shorten innovation shelf lives, prompting some entities to reconsider publishing papers or filing patents, while US firms must pivot to inventing new modalities to remain competitive.
- The industry faces a trend of stacking new medicines on existing ones (Eroom's Law), with a shift anticipated toward direct-to-consumer business models and larger indications driven by GLP-1 successes and the need to replace blockbuster patents.
- Regulatory reform is urged to lower per-patient trial costs from $10,000 to $500,000 levels and establish "orphan drug" style designations for common age-related diseases.
- Aging therapeutics are projected to arrive in waves, beginning with small-molecule modalities like GLP-1s and potentially dog-approved drugs before human approval, aiming to extend median lifespans by 2.5 years in primates and potentially to ages 75–80 by eliminating heart attacks.
- Future innovation will diversify into orthogonal new modalities, with drugs evolving into hybrid information and diagnostic products, potentially creating markets that do not currently exist.
- Value creation is expected to polarize between proprietary platforms for unique capabilities and consolidated platforms for commoditization, mirroring the evolution of sequencing technology.